US EditionPublished • loading... • Updated
Clywedog Therapeutics Announces Activation of All Centers and Patient Dosing in Multicenter, International Phase 1b Clinical Study of Balomenib in Type 2 Diabetes
Summary by PR Newswire
33 Articles
33 Articles
Bennington Banner+32 Reposted by 32 other sources
Clywedog Therapeutics Announces Activation of All Centers and Patient Dosing in Multicenter, International Phase 1b Clinical Study of Balomenib in Type 2 Diabetes
DOVER, Del., Dec. 17, 2025 /PRNewswire/ -- Clywedog Therapeutics, Inc., a clinical-stage biotechnology company advancing novel therapies for metabolic diseases, today announced the activation of all clinical centers and patient dosing in its multicenter, international Phase 1b randomized, double-blind, placebo-controlled…
Coverage Details
Total News Sources33
Leaning Left2Leaning Right2Center9Last UpdatedBias Distribution69% Center
Bias Distribution
- 69% of the sources are Center
69% Center
L 16%
C 69%
15%
Factuality
To view factuality data please Upgrade to Premium
